Quality of life consequences of chemotherapy-induced emesis

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Quality of Life Research

• Publication date

  1992-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00434947PMID 1299465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population.

  1989cited by this paper
• Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.

  1984cited by this paper
• Nausea and Vomiting as Major Complications of Cancer Chemotherapy

  1983cited by this paper
• On the receiving end--patient perception of the side-effects of cancer chemotherapy.

  1983cited by this paper
• Multivariate data analysis : an introduction

  1983cited by this paper

• The dorsolateral prefrontal cortex as a potential target for electrical stimulation in the treatment of vestibular‐based nausea

  2026cites this paper
• To Study the Impact of Ultrasound-Assisted Antisolvent Crystallization on Aprepitant Crystal Habits

  2026cites this paper
• Development and validation of the Pediatrics Functional Living Index—Emesis scale

  2025cites this paper
• Validation of Steroid-Sparing Therapy in Patients Receiving Oxaliplatin-based Chemotherapy: A before-and-after Prospective Observational Study

  2025cites this paper
• A novel SadP-scFv UCHT1 lectibody activates T cells and mediates lysis of Burkitt's lymphoma cells

  2025cites this paper
• Efficacy of 5-hydroxytryptamine 3 receptor antagonists versus metoclopramide for preventing nausea and vomiting during azacitidine chemotherapy in patients with myelodysplastic syndromes or acute leukemia: a retrospective observational study

  2025cites this paper
• Association of chemotherapy-induced nausea and vomiting or anorexia with plasma levels of five gastrointestinal peptides in patients receiving chemotherapy

  2025cites this paper
• Green Tea Leaves and Rosemary Extracts Selectively Induce Cell Death in Triple-Negative Breast Cancer Cells and Cancer Stem Cells and Enhance the Efficacy of Common Chemotherapeutics

  2024cites this paper
• Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea

  2024cites this paper
• Establishing a nausea-free ward model to reduce chemotherapy-induced nausea and vomiting: A retrospective study

  2024cites this paper
• Neiguan (PC6) acupoint stimulation for preventing chemotherapy-induced nausea and vomiting: a cost-effective supplement in guideline-inconsistent chemotherapy-induced nausea and vomiting prophylaxis subgroup.

  2024cites this paper
• Prevalence of anticipatory nausea and vomiting in breast cancer patients undergoing highly emetogenic chemotherapy

  2024cites this paper
• Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal

  2023cites this paper
• Targets and study design for symptom-focused trials aimed at patients with cirrhosis: An expert consensus

  2023cites this paper
• A Shiga Toxin B-Subunit-Based Lectibody Boosts T Cell Cytotoxicity towards Gb3-Positive Cancer Cells

  2023cites this paper
• Patient-reported outcome measures for medication-related quality of life: A scoping review.

  2022cites this paper
• Assess and Evaluation the Quality of Life (QoL) Among Cancer Patients Undergoing Treatment by Using EORTC QLQ-30 Scale

  2022cites this paper
• Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy

  2022cites this paper
• Employing cognitive interviewing to evaluate, improve and validate items for measuring the health-related quality of life of women diagnosed with ovarian cancer

  2022cites this paper
• Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial

  2022cites this paper
• The efficacy of aprepitant in salvage treatment of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy for patients with gastrointestinal cancer

  2021cites this paper
• Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ quality of life: An Arabic version of the Functional Living Index-Emesis

  2021cites this paper
• Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women

  2021cites this paper
• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.

  2021cites this paper
• Exploring the nausea experience among female patients with breast cancer; A pilot interview study

  2020cites this paper
• Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301)

  2020cites this paper
• Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies.

  2020cites this paper
• Comparison of Mirtazapine and Olanzapine on Nausea and Vomiting following Anthracycline-cyclophosphamide Chemotherapy Regimen in Patients with Breast Cancer

  2020cites this paper
• Transplant-Related Non-pain Issues: Prevention, Intervention, and Limitations

  2020cites this paper
• Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-In Pilot Randomized Clinical Trial.

  2020cites this paper
• Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis

  2020cites this paper
• Breast Cancer Patients’ Perceptions of Their Experience With Chemotherapy-Induced Nausea and Vomiting and Its Impact on Quality of Life in Jeddah, Saudi Arabia

  2020cites this paper
• Antiemetic Prophylaxis and Anesthetic Approaches to Reduce Postoperative Nausea and Vomiting in Bariatric Surgery Patients: a Systematic Review

  2020cites this paper
• Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial

  2020cites this paper
• Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review.

  2020cites this paper
• Application of electroacupuncture for postoperative pain management after total knee arthroplasty: a study protocol for a single-blinded, randomised placebo-controlled trial

  2019cites this paper
• One‐Day Versus Three‐Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy‐Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data‐Based Meta‐Analysis

  2019cites this paper
• Quality of life of cancer patients living in Trinidad and Tobago

  2019cites this paper
• Efficacy of olanzapine for quality of life improvement among patients with malignant tumor: A systematic review

  2019cites this paper
• Colorectal Cancer : Consequences of Chemotherapy Induced Nausea and Vomiting on Patients ’ Functional Daily Living

  2019cites this paper
• Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy

  2019cites this paper
• [Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines].

  2019cites this paper
• The prevalence and configuration of nausea in patients receiving intravenous chemotherapy in a private oncology centre in South Africa

  2019cites this paper
• The Impact on Quality of Life of Highly Effective Antiemetic Therapy among Breast Cancer Patients Receiving Anthracycline Plus Cyclophosphamide-based Regimen

  2018cites this paper
• Development and psychometric validation of the Nausea/Vomiting Symptom Assessment patient-reported outcome (PRO) instrument for adults with secondary hyperparathyroidism

  2018cites this paper
• Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.

  2018cites this paper
• Health Related Quality of Life of Cancer Patients in Ethiopia

  2018cites this paper
• AWARENESS OF CHEMOTHERAPY SIDE EFFECTS AND ATTITUDE TOWARDS CHEMOTHERAPY USE AMONG CANCER PATIENTS ATTENDING ONCOLOGY CLINIC AT BUGANDO MEDICAL CENTRE, IN MWANZA, NORTHERN TANZANIA

  2018cites this paper
• Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study.

  2018cites this paper
• Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131)

  2018cites this paper
• Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis

  2018cites this paper
• Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool.

  2018cites this paper
• Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia

  2018cites this paper
• Impact of radiation-induced nausea and vomiting on quality of life

  2018cites this paper
• A literature review on prevention of chemotherapy-induced nausea and vomiting using netupitant/palonosetron

  2018cites this paper
• Health Literacy and Patient -Reported Outcomes

  2018cites this paper
• A pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting.

  2018cites this paper
• Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy

  2018cites this paper
• Fixed Combination Antiemetic

  2018cites this paper
• Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis.

  2018cites this paper
• Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta‐analyses of randomized controlled trials

  2017cites this paper
• Ginger—Mechanism of action in chemotherapy-induced nausea and vomiting: A review

  2017cites this paper
• Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP.

  2017cites this paper
• Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open‐Label Pivotal Study

  2017cites this paper
• The Effectiveness of Hologram Bracelets in Reducing Chemotherapy-Induced Nausea and Vomiting Among Adult Patients With Cancer

  2017cites this paper
• The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial

  2017cites this paper
• Mixed outpatient–inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment

  2017cites this paper
• Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial

  2017cites this paper
• Evaluating the antiemetic administration consistency to prevent chemotherapy-induced nausea and vomiting with the standard guidelines: a prospective observational study

  2017cites this paper
• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis

  2017cites this paper
• Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting in adults

  2016cites this paper
• Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

  2016cites this paper
• n-3 polyunsaturated fatty acid supplementation during cancer chemotherapy

  2016cites this paper
• [Perceptual gap between oncologists/oncology nurses and patients in the management and impact of chemotherapy/radiotherapy-induced nausea and vomiting: French results of the GAP survey].

  2016cites this paper
• Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis

  2016cites this paper
• Maximizing Function and Quality of Life of Patients with Glioblastoma after Surgical Resection: A Review of Current Literature

  2016cites this paper
• Postoperative Nausea and Vomiting: A Practical Guide

  2016cites this paper
• Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.

  2016cites this paper
• Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.

  2016cites this paper
• Écarts d’évaluation entre oncologues, infirmiers et patients dans la prise en charge et l’impact des nausées et vomissements chimio/radio-induits : résultats français de l’enquête GAP

  2016cites this paper
• Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy

  2016influential citation
• Role of Psychosocial Variables on Chemotherapy-Induced Nausea and Vomiting and Health-Related Quality of Life among Cancer Patients: A European Study

  2015cites this paper
• Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey

  2015cites this paper
• Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool

  2015cites this paper
• Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin

  2015cites this paper
• Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary

  2015cites this paper
• Standardized ginger (Zingiber officinale) extract as a treatment for chemotherapy-induced nausea and vomiting: efficacy, safety and feasibility.

  2015cites this paper
• Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron

  2015cites this paper
• A Comparison of 5-HT3 Receptor Antagonist and Metoclopramide in the Patients Receiving Chemotherapeutic Regimens Including CMF, CAF and CHOP

  2015cites this paper
• Symptom clusters of gastrointestinal cancer patients undergoing radiotherapy using the Functional Living Index—Emesis (FLIE) quality-of-life tool

  2015cites this paper
• Advances in Side Effect Management

  2015cites this paper
• Ea versus Sham Acupuncture and no Acupuncture for the Control of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting: A Pilot Study

  2015cites this paper
• Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.

  2015cites this paper
• Étude de la qualité de vie dans les néoplasies ovariennes : outils et enjeux

  2015cites this paper
• Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.

  2015cites this paper
• Palonosetron in combination with 1‐day versus 3‐day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase‐II trial

  2015cites this paper
• [Health-related quality of life in patients treated for ovarian cancer: tools and issues].

  2015cites this paper
• Electroacupuncture via Chronically Implanted Electrodes: Potential Treatment for Chemotherapy‐Induced Delayed Emesis

  2015cites this paper
• Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.

  2015cites this paper
• Prevalence of Chemo-induced Nausea and Vomiting, and Its impact on Patients' Quality of Life at the Oncology Unit of Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia

  2015cites this paper